Skip to main content

PRECISION MEDICINE IN PORTAL VEIN THROMBOSIS: IDENTIFICATION OF NEW THERAPEUTIC TARGETS AND DEVELOPMENT OF A UNIQUE THERANOSTIC APPROACH

PI20/00569

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de Investigación en Salud
Call year 2020
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre INSTITUTO DE INVESTIGACIONES BIOMEDICAS AUGUST PI I SUNYER (IDIBAPS)
Execution centre INSTITUTO DE INVESTIGACIONES BIOMEDICAS AUGUST PI I SUNYER (IDIBAPS)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Persistent varices in cured patients, Understanding the role of hepatic venous pressure gradient

  • Olivas, Pol|||0000-0002-1919-0284
  • Soler-Perromat, Alexandre|||0000-0003-2531-2484
  • Tellez, L.
  • Carrión Rodríguez, José Antonio|||0000-0001-7191-6081
  • Alvarado-Tapias, Edilmar|||0000-0003-2036-6133
  • Ferrusquía-Acosta, José|||0000-0001-8034-1291
  • Lens, Sabela|||0000-0003-4900-411X
  • Guerrero, A.
  • Falgà Tirado, Angeles
  • Vizcarra, Pamela
  • Orts, Lara|||0000-0002-3070-0310
  • Pérez Campuzano, Valeria|||0000-0002-5997-9511
  • Shalaby, Sarah|||0000-0002-8700-6282
  • Torres, Sonia
  • Baiges, Anna|||0000-0002-6963-9203
  • Turon, Fanny|||0000-0001-5940-2838
  • García-Pagán, JC.|||0000-0001-9032-4954
  • García Criado, Ángeles|||0000-0003-3536-4288
  • Hernández-Gea, Virginia|||0000-0001-7937-984X
Etiologic factor removal (ER) drives recompensation and improves portal hypertension in cirrhosis. Esophageal varices (EV) and portosystemic shunts (PSS) have been found in patients despite hepatic venous pressure gradient (HVPG) dropping below 10 mmHg after ER, questioning HVPG accuracy in reflecting true portal pressure in the setting of ER. We aim to evaluate the correlation of HVPG with direct portal pressure (DPP) in patients with persistence of EV after ER despite HVPG <10 mmHg. Methods: This is a bicentric 'proof of concept' study evaluating HVPG and ultrasound-guided percutaneous DPP in patients with HCV or alcohol-related cirrhosis with persistent varices and HVPG <10 mmHg after at least 5 years of ER. Seven patients with HCV and three with alcohol-related cirrhosis with persistent varices and HVPG <10 mmHg after at least 5 years of ER were included. At evaluation, all patients had a patent portal vein and were compensated. The median platelet count was 129.5 (IQR 95-145) × 10/ml, and the median liver stiffness measurement was 16.15 (IQR 14.4-22.3) kPa. In five patients, EV remained the same size (two large and three small), and five downsized to small after ER. Wedge hepatic vein pressure (median 19 [IQR 16.5-20] mmHg) and portal pressure (median 18 [IQR 15-19.5] mmHg) had an excellent correlation (R = 0.93, p <0.0001). Portal pressure gradient (PPG) confirmed the absence of clinically significant portal hypertension as identified by HVPG across all the patients. HVPG accurately reflects PPG in the context of HCV and alcohol-related cirrhosis regression. After ER, EV may persist despite HVPG <10 mmHg. The benefit of prophylaxis in patients with EV and HVPG <10 mmHg is unknown. Future studies with clinical endpoints are needed to validate our findings. Despite a favorable evolution after the removal of the etiologic factor, varices persist in some patients, and there is a lack of concise guidelines for the evaluation and management of portal hypertension in this population. Our research underscores the persistence of varices in the absence of clinically significant portal hypertension and significantly demonstrates the accuracy of hepatic venous pressure gradient (HVPG) in reflecting portal vein pressure in this specific patient group. These findings emphasize the crucial role of HVPG in the assessment of portal hypertension after etiologic factor removal and lay the groundwork for further investigation into clinical outcomes and the necessity of non-selective beta-blockers in individuals with persistent varices after the removal of etiologic factor.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Impact of SARS-CoV-2 vaccination in patients with vascular liver diseases, Observations from a VALDIG multicenter study

  • Pérez Campuzano, Valeria|||0000-0002-5997-9511
  • Rautou, Pierre-Emmanuel|||0000-0001-9567-1859
  • Marjot, Thomas
  • Praktiknjo, Michael|||0000-0001-7033-9956
  • Alvarado-Tapias, Edilmar|||0000-0003-2036-6133
  • Turco, Laura|||0000-0001-8148-3769
  • Ibáñez Samaniego, Luis|||0000-0002-0309-2727
  • González-Alayón, C.|||0000-0003-0215-4874
  • Puente, Ángela
  • Llop, Elba
  • Simón Talero, Macarena|||0000-0002-1409-3936
  • Álvarez-Navascués, Carmen
  • Reiberger, Thomas|||0000-0002-4590-3583
  • Verhelst, Xavier|||0000-0002-2798-5415
  • Tellez, Luis
  • Bergmann, JJohanna Birte
  • Orts, Lara|||0000-0002-3070-0310
  • Grassi, Giuseppe
  • Baiges, Anna|||0000-0002-6963-9203
  • Audrey, Payance|||0000-0003-1174-8375
  • Trebicka, Jonel|||0000-0002-7028-3881
  • Villanueva, Càndid|||0000-0002-3674-914X
  • Morelli, Maria Cristina|||0000-0002-9742-1981
  • Murray, Sam
  • Meacham, Georgina|||0000-0003-1929-4152
  • Luetgehetmann, Marc
  • Schulze zur Wiesch, Julian|||0000-0002-5033-1938
  • García-Pagán, JC.|||0000-0001-9032-4954
  • Barnes, Eleanor
  • Plessier, Aurélie|||0000-0001-5656-1622
  • Hernández-Gea, Virginia|||0000-0001-7937-984X
Background & Aims: Patients with vascular liver diseases (VLD) are at higher risk of both severe courses of COVID-19 disease and thromboembolic events. The impact of SARS-CoV-2 vaccination in patients with VLD has not been described and represents the aim of our study. Methods: International, multicenter, prospective observational study in patients with VLD analyzing the incidence of COVID-19 infection after vaccination, severity of side effects, occurrence of thromboembolic events and hepatic decompensation. In a subgroup of patients, the humoral and cellular responses to vaccination were also analyzed. Results: A total of 898 patients from 14 European centers - part of the VALDIG network - were included, 872 (97.1%) patients received two vaccine doses (fully vaccinated), and 674 (75.1%) three doses. Of the total cohort, 151/898 had a COVID-19 infection prior to vaccination, of whom 9/151 (5.9%) were re-infected. Of the 747/898 patients who were not previously infected, 11.2% (84/747) were diagnosed with a COVID-19 infection during the study period. Two infected patients required intensive care unit admission and infection was fatal in two fully vaccinated patients. Adverse effects were reported in around 40% of patients, with local side effects being the most frequent. During the study period, 31 (3.5%) patients had thromboembolic events and 21 (2.3%) hepatic decompensations. No cases of vaccine-induced thrombocytopenia were reported. Vaccine immunogenicity was assessed in 36 patients; seroconversion reached 100% and IFNy T-cell responses significantly increased post two mRNA-1273 vaccine doses. Conclusion: Patients with VLD seem to have a preserved immune response to SARS-CoV-2 vaccination, which appears to be safe and effective in preventing severe COVID-19 infection. Our study cannot definitively establish a direct link between vaccination and thrombotic events, though the contribution of vaccination as a cofactor in VLD remains to be elucidated. Impact and implications: Patients with vascular liver disease (VLD) are at increased risk of both SARS-CoV-2 infection and severe COVID-19 disease. The potential risks associated with vaccination against this infection need thorough investigation. Our research enhances the understanding of the effects of COVID-19 vaccination in patients with VLD, highlighting its good tolerability. Moreover, patients with VLD appear to have a preserved immune response to SARS-CoV-2 vaccination, providing protection against severe COVID-19 infection. Our study cannot definitively establish a direct link between vaccination and thrombotic events, and no cases of vaccine-induced thrombocytopenia were reported.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The Interplay between Pathophysiological Pathways in Early-Onset Severe Preeclampsia Unveiled by Metabolomics

  • Youssef, Lina|||0000-0002-0554-5507
  • Crovetto, Francesca|||0000-0003-0140-7411
  • Simoes, Rui Vasco|||0000-0001-7574-4723
  • Miranda, Jezid|||0000-0003-0372-8374
  • Paules, Cristina|||0000-0001-6795-0367
  • Blasco Pelicano, Miquel|||0000-0003-0789-7992
  • Palomo, Marta|||0000-0002-3261-6577
  • García Calderó, Héctor|||0000-0002-8801-6394
  • Tura-Ceide, Olga|||0000-0003-4334-9790
  • Dantas, A. P|||0000-0001-8514-4094
  • Hernández-Gea, Virginia|||0000-0001-7937-984X
  • Herrero, Pol|||0000-0002-8746-7214
  • Canela, Núria|||0000-0003-0261-2396
  • Campistol Plana, Josep M.|||0000-0002-6841-1119
  • Garcia Pagan, Joan Carles
  • Diaz-Ricart, Maribel|||0000-0003-1122-0052
  • Gratacós, Eduard|||0000-0002-7405-7224
  • Crispi, Fatima|||0000-0002-7422-5240
Introduction: Preeclampsia is a multi-system disorder unique to pregnancy responsible for a great part of maternal and perinatal morbidity and mortality. The precise pathogenesis of this complex disorder is still unrevealed. Methods: We examined the pathophysiological pathways involved in early-onset preeclampsia, a specific subgroup representing its most severe presentation, using LC-MS/MS metabolomic analysis based on multi-level extraction of lipids and small metabolites from maternal blood samples, collected at the time of diagnosis from 14 preeclamptic and six matched healthy pregnancies. Statistical analysis comprised multivariate and univariate approaches with the application of over representation analysis to identify differential pathways. Results: A clear difference between preeclamptic and control pregnancies was observed in principal component analysis. Supervised multivariate analysis using orthogonal partial least square discriminant analysis provided a robust model with goodness of fit (R X = 0.91, p = 0.002) and predictive ability (Q Y = 0.72, p < 0.001). Finally, univariate analysis followed by 5% false discovery rate correction indicated 82 metabolites significantly altered, corresponding to six overrepresented pathways: (1) aminoacyl-tRNA biosynthesis; (2) arginine biosynthesis; (3) alanine, aspartate and glutamate metabolism; (4) D-glutamine and D-glutamate metabolism; (5) arginine and proline metabolism; and (6) histidine metabolism. Conclusion: Metabolomic analysis focusing specifically on the early-onset severe form of preeclampsia reveals the interplay between pathophysiological pathways involved in this form. Future studies are required to explore new therapeutic approaches targeting these altered metabolic pathways in early-onset preeclampsia.